COMPARISONS OF FIBRO Q INDEX AND FIB-4 IN VARIOUS STAGES OF CHRONIC B HEPATITIS
DOI:
https://doi.org/10.24293/ijcpml.v25i1.1508Keywords:
Chronic B hepatitis, Fibro Q, FIB-4, fibroscanAbstract
Fibro Q and FIB-4 index are non-invasive biomarkers to evaluate liver fibrosis in chronic hepatitis. This study aimed to evaluate and compare the diagnostic accuracies of Fibro Q and FIB-4 index compared with fibroscan in chronic B hepatitis. This research was a cross-sectional study including 145 patients with chronic B hepatitis who had a fibroscan examination at the Dr.Wahidin Sudirohusodo Hospital during July 2014-June 2016. The clinical data included sex, age, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), platelet, Prothrombin Time (PT)/International Normalized Ratio (INR). Fibro Q and FIB-4 index were compared with fibroscan to predict various fibrotic degrees of chronic B hepatitis patients. There were significant differences compared to fibroscan, the highest Fibro Q average was found in the medium degree of fibrosis and the lowest in the normal fibroscan (p<0.01) while the highest FIB-4 average was found in the high degree of fibrosis and the lowest in the normal fibroscan (p<0.001). Fibro Q sensitivity and specificity test against fibroscan have AUC value of 0.579 by using a 9.33 cut-off with a sensitivity of 80.5% and specificity of 28.1%, while FIB-4 has AUC value of 0.723 by using cut-off 14.31 with sensitivity 80.5% and specificity 46.9%. These results show that both Fibro Q and FIB-4 index can be used to assess liver cirrhosis as well as fibroscan. FIB-4 Index has a better diagnostic value compared to Fibro Q, so this marker can be used as a simple screening instrument.Downloads
References
Soemohardjo S, Gunawan S. Hepatitis B kronik. Buku ajar ilmu penyakit dalam. Jakarta, Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia, 2013; 5(2): 435-440.
Kementerian Kesehatan RI. Pusat data dan informasi hepatitis. Jakarta, Riset Kesehatan Dasar (Riskesdas), 2013; 1-8.
Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Beijing, China, Libertas Academica Ltd, Biomarker Insights, 2012; 7: 105–117.
Kay Seto W, Fan Lee C, Lung Lai C, Ip PPC, Tak Fong DY, et al. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. Hongkong, PLoS One, 2011; 6(8): 1-7.
Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. London, Annals of Gastroenterology, 2012; 25: 218-231.
Åžirli R, Sporea I, Bota S, Popescu A, Cornianu M. A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. Timisoara, Romania, University of Medicine and Pharmacy, Hepatitis Monthly, 2010; 10(2): 88-94.
Parsian H, Alizadeh M, Yahyapour Y. Clinical application of non-invasive markers of liver fibrosis. Iran, INTECH, 2013; 4: 91-110.
Fallatah HI. Noninvasive biomarkers of liver fibrosis: An overview. Saudi Arabia, Hindawi Publishing Corporation, 2014; 1-15.
Hsieh YY, Tung SY, Lee IL. Lee K, Shen CH, et al. Fibro Q: An easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Taiwan, Chang Gung Med, 2009; 32(6): 614-22.
Huang R, Jiang N, Yang R, Geng X, Lin J, et al. Fibroscan improves the diagnostic sensitivity of liver fibrosis in patients with chronic hepatitis B, experimental and therapeutic medicine. China, 2016; 11: 1673-1677.
Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, et al. Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver International, 2009; 29: 242-247.
Zeng X, Xu C, He D, Li M, Zhang H, et al. Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. China, Croat Med J, 2015; 56: 272-9.
Mallet V, Venier D, Roussin C, Bourliere M, Pettinelli ME, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. France, Blackwell Publishing, 2009; 409-415.
Yuanyuan L, Chen Y, Zhao Y. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: A meta-analysis. Department of Laboratory Medicine. China, PLoS One, 2014; 1-13.
Ydreborg M, Lisovskaja V, Lagging M, Christensen PB, Langeland N, et al. A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. Sweden, PLoS One, 2014; 9(4): 1-8.
Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, et al. Performance of the aspartate aminotransferase to platelet ratio index for the staging of hepatitis c-related fibrosis: An updated meta-analysis. Hepatology, 2011; 53(3): 726-736.
